~~<i id='C6EF53990E'><strike id='C6EF53990E'><tt id='C6EF53990E'><pre id='C6EF53990E'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

leisure time

comprehensive

author：fashion 2025-09-05 09:16:44 - browse：435

JOHNSON & JOHNSON HEADQUARTERS — Daniel Hulshizer/AP

Eight months into his tenure, Johnson & Johnson’s R&D chief is putting a big emphasis on medicines for cancer, treatment-resistant depression, and autoimmune disease.

To sharpen that focus, R&D chief John Reed told STAT that the company is de-emphasizing two areas that have been mainstays for the drug and medical device giant: infectious disease and vaccines, as well as medicines targeting kidney disease and rare eye conditions.

The disclosures were made in an interview ahead of an investor meeting Reed is leading Tuesday aimed at generating excitement about the company’s research and development efforts.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How one medical school became remarkably diverse
Next article： Medicaid, Medicare dual

Wikipedia

hotspot

focus

knowledge

AtableladenwithPPEandmedicalsuppliessuchassplitsponges,disposablebloodpressurecuffs,andgloves.DavidJ

WSS

Readout Newsletter: H5N1 bird flu vaccine, Cytokinetics, Gilead

Study finds gene variants tied to breast cancer risk in Black women

Researchers use wearables data and AI to predict preterm birth risk

Cigna to pay $172 million to settle Medicare Advantage fraud probe

Would Medicare drug price negotiations stall in a shutdown?

Addressing health care workers' trauma can help fight burnout

leisure time

comprehensive

Wikipedia

Hepatitis C has a cure — but many Americans still lack access to it

Cytokinetics CEO Robert Blum is on my Worst CEO shortlist again

Medical leaders decry Supreme Court decision on affirmative action

H5N1 bird flu outbreak: Second human case reported, in Michigan

Activists slam private health insurers over coverage restrictions

Health tech startups drop sharply from 2021 highs

How one medical school became remarkably diverse

Making the case for fair compensation in clinical trials

United colonoscopy coverage change 'may cost lives,' doctors say

Address the ethical violations that led to 'Three Identical Strangers'

hotspot

Fentanyl is making it harder to start addiction treatment

Citing H5N1 threat, CDC urges peak flu monitoring this summer

Liver decline slowed by off

After a drawn out lobbying fight, ARPA

After a drawn out lobbying fight, ARPA

Intercept Pharmaceuticals sells itself for less than $1 billion

focus

focus

knowledge

knowledge